MORRISTOWN, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer, will give a corporate presentation at the J.P. Morgan 41st Annual Healthcare Conference. Intercept’s presentation is scheduled for Thursday, January 12, at 12:00 p.m. Pacific Time.
A live audio webcast of the event can be found here. The webcast will also be available on the investor page of Intercept’s website as an audio archive for approximately four weeks following the presentation.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH) and severe alcohol-associated hepatitis (sAH). For more information, please visit www.interceptpharma.com or connect with the Company on Twitter and LinkedIn.
Contact
For more information about Intercept, please contact:
Investor inquiries: investors@interceptpharma.com
Media inquiries: media@interceptpharma.com
Vancouver, British Columbia--(Newsfile Corp. - March 26, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB:…
Proposed business combination to create a North American technology company with an AI-driven fintech marketplace.…
NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Chronic pain affects millions of…
Oakville, Ontario--(Newsfile Corp. - March 25, 2024) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF)…
Conference call to discuss financial and operational results scheduled for Tuesday, March 26 at 8:30…
VANCOUVER, BC / ACCESSWIRE / March 25, 2024 / Bruush Oral Care Inc. (NASDAQ:BRSH) (the…